Sign-Up for Launch of VERSE Equity Toolkit

 

 
Vaccine Access Digest

May 2022
Johns Hopkins University
Bloomberg School of Public Health

Register: Official Launch of the VERSE Equity Toolkit For Multidimensional Equity Assessments 

Join us for the official launch of the Vaccine Economics Research for Sustainability and Equity (VERSE) Equity Toolkit, which compares the level of vaccine coverage against the level of equity and quantifies the influence of key sociodemographic factors to inequity. The toolkit uses novel methodologies to rank a country’s population by level of composite disadvantage which is composed of known factors that fairly and unfairly influence access to and uptake of vaccines. IVAC's health economist, Dr. Bryan Patenaude, and fellow economist, Dr. Elizabeth Ekirapa Kiracho, at Makerere University, Uganda will discuss the development, uses, and policy implications of the toolkit. Access the toolkit.
Read the full announcement published on ImmunizationEconomics.org.

Read the paper published in Social Science & Medicine.
Register
 

Highlights from World Immunization Week 2022
 
 
imageWatch Webinars from World Immunization Week 2022
IVAC along with global immunization and Indigenous health partners, hosted three webinars. Recordings are available and free to view on our YouTube channel.

Share Messages about #LongLifeForAll
Continue promoting the value of vaccines by sharing these social media messages. View our toolkit here.
 

Vaccine News and Resources
 
 

Rotavirus Vaccine Series of Briefs—Newly Updated

Six rotavirus-focused briefs, produced by the ROTA Alliance, cover epidemiology and disease burden, available vaccine products, the impact of vaccination, economic costs of rotavirus disease and the value of vaccines, safety, and introduction and coverage status. The Council’s series also includes a supplemental brief on the broad impact of early childhood diarrhea.
 
 

#ICYMI: VARN2022 Conference Session Recordings

For those unable to attend, the Sabin Vaccine Institute and its Vaccination Acceptance Research Network (VARN) Conference recorded these engaging sessions, which are available to watch for free online. IVAC presented during the following sessions:
 

Study Finds That Children’s Antibody Responses to COVID-19 Are Stronger Than Adults’

new study suggests that children tend to have strong antibody responses after SARS-CoV-2 infection. Understanding antibody responses to SARS-CoV-2 at different ages can inform COVID-19 vaccine strategies and policies. The findings are published in JCI Insight.
 

IVAC and VALUE Baltimore Project Launch COVID-19 Information Compendium

The VALUE (Vaccine Acceptance & Access Live in Unity, Engagement, and Education) Baltimore Project, which aims to improve COVID-19 vaccine acceptance in Baltimore City, has created a new resource for anyone seeking up-to-date information about COVID-19. The Compendium of Information on COVID-19 Vaccination and Communications is a living document that is continuously updated with new COVID-19 information and policy.
 

Katherine L. O'Brien Awarded Jimmy and Rosalynn Carter Humanitarian Award
Dr. Katherine O'Brien, IVAC's former executive director, was awarded the prestigious 2022 Rosalyn and Jimmy Carter Humanitarian Award by the National Foundation for Infectious Diseases for her career contributions to global vaccine equity. View all recipients here.
 

Recent Publications
 

Conspiracy theories and misinformation about COVID-19 in Nigeria: Implications for vaccine demand generation communications
Authors include Chizoba Wonodi and Ruth Karron
This paper published in Vaccine provides the first thematic analysis of circulating misinformation about COVID-19 in Nigeria. Based on data collected, people throughout the country are exposed to misinformation on COVID-19 and the vaccine. Collecting data on public opinion about COVID-19 will help future efforts to counter vaccine hesitancy.
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression 
Authors include Daniel Feiken, Melissa Higdon, Katherine O'Brien, and Maria Deloria Knoll
This meta-analysis published in The Lancet found that COVID-19 vaccine efficacy or effectiveness against severe disease remained high, but did slightly decrease six months after full vaccination. By contrast, vaccine efficacy or effectiveness against infection and symptomatic disease decreased approximately 20–30 percentage points by six months. This evaluation is important for updating COVID-19 vaccine policy.
Rubella
By Amy Winter and William Moss
In a seminar on rubella published in The Lancet, the authors describe in-depth rubella's epidemiology, virology, diagnosis, management, and elimination. While the timeline for eradicating rubella is uncertain, reducing its burden is promising with current rubella vaccines. New technologies like microarray patches could make it even easier to vaccinate hard-to-reach populations like zero-dose children.
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants
Authors include Laura Hammitt
This study published in The New England Journal of Medicine evaluated the efficacy of nirsevimab, a monoclonal antibody treatment against respiratory syncytial virus (RSV), in infants. A single injection of nirsevimab administered before the RSV season protected healthy late-preterm and term infants from medically attended RSV-associated lower respiratory tract infection.
 

IVAC in the News
 

Gavi's VaccinesWork: Using Geospatial Mapping to Find Zero-Dose Children in Zambia

Hub: Chatbots Battle COVID-19 Vaccine Hesitancy

MintTackling the COVID Disruption of Regular Childhood Immunization
  
Gavi's VaccinesWorkIs the COVAX Facility Ensuring Equitable Vaccine Distribution?

PoliticoKids are Behind on Routine Immunizations. COVID Vaccine Hesitancy isn't Helping.
 
NPR (Radio): The World Health Organization Approves a New Polio Vaccine for Emergency Use
  
The Baltimore Sun: COVID Vaccines will Soon be Available for Kids Under 5. Experts Worry Many Parents Won’t See the Need.

Public Good NewsHow Misinformation Tricks our Brains 

 
 

Copyright © 2022 IVAC, All rights reserved.

For Media Inquiries, contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.


image    image
Twitter
Website